Unless all populations are represented adequately in trials, it will be hard to know if a drug works the same in all populations as it does in one specific one, explained Robert Dellavalle, MD, PhD, MSPH, of University of Colorado School of Medicine and Rocky Mountain Regional VA Medical Center.
Adequate representation in clinical trials is important to ensure therapies work the same in various populations, said Robert Dellavalle, MD, PhD, MSPH, professor, Department of Dermatology, Department of Epidemiology, University of Colorado School of Medicine, and chief of Dermatology, Rocky Mountain Regional VA Medical Center. However, a review of recent trials for hidradenitis suppurativa found certain populations were underrepresented.
In a poster1 presented at the American Academy of Dermatology annual meeting, Dellavalle and colleagues searched PubMed and ClinicalTrials.gov for phase 2 and 3 trials for hidradenitis suppurativa to gain an understanding of the current state of clinical trials for the disease in 2022. Of the 59 trials included in the analysis, 34 had monoclonal antibodies as the primary intervention. Of the studies that included race/ethnicity information, 82.86% of patients with data were White, which indicated non-White patients with hidradenitis suppurativa were underrepresented in the studies in 2022.
Dellavalle spoke with The American Journal of Managed Care® (AJMC®) about the results of the poster and the importance of diversity in clinical trials.
AJMC: A poster you presented at the annual meeting of the American Academy of Dermatology found Black patients have the highest prevalence of HS but are disproportionately underrepresented in trials. What implications does this have for treatment decisions in the real world?
Dellavalle: How different is the response in different groups to medications? How generalizable are the clinical trials? Until we have representative populations in the clinical trials we do, it will be hard to say that the drugs work as well in all of the different populations as they do in one particular population. I think that's the goal in dermatology—to bring more diversity to our patient population and clinical trials. To do that, we're going to have to build trust as a medical enterprise with people that have not been well served in the past that have rightful suspicions with the medical enterprise. Acknowledging that problem is the first step.
AJMC: What are the benefits of using biologic treatments to treat hidradenitis suppurativa over nonbiologic treatments and vice versa?
Dellavalle: Hidradenitis suppurative is a terrible disease; I would not wish on anybody to have festering sores in your private areas and underarms that really inhibit your quality of life. And we just do not have any treatments that adequately address this problem. And it's wonderful to have a new treatment like biologics that can be used to improve the quality of life of some of those patients. It's not a magic bullet, but it is an addition to the armamentarium that we can use for this terrible disease.
Reference
Mulligan KM, O’Connell KA, Kim L, et al. Demographic and therapeutic trends in clinical trials for hidradenitis suppurativa. Presented at: 2023 American Academy of Dermatology annual meeting; March 17-21, 2023; New Orleans, LA. Poster 42824.
A new federal rule will enable thousands of immigrants in the Deferred Action for Childhood Arrivals (DACA) program to obtain health care through the Affordable Care Act; a forthcoming CMS rule is expected to lower home-based care wait times and raise caregiver wages; the HHS Office for Civil Rights has finalized 2 rules that strengthen the ACA’s health care discrimination ban.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More